NEW YORK, NY / ACCESSWIRE / July 13, 2018 / U.S. markets made it in the green on Thursday, pushed higher by rally in information technology and telecom stocks, covering continued uncertainty over trade policy. The Dow Jones Industrial Average gained 0.91 percent to close at 24,924.89, while the S&P 500 Index increased 0.87 percent to close at 2,798.29. The Nasdaq Composite Index jumped 1.39 percent to close at 7,823.92.
Head of small and mid-cap equities at Aberdeen Standard Investments, Ralph Bassett said, “The market is breathing a sign of relief despite some pretty intense headlines recently. We’re seeing technology pick up, and other areas more broadly as well, as fundamentals remain very good.”
RDI Initiates Coverage on:
Johnson & Johnson
Johnson & Johnson's stock moved 1.2% higher Thursday, to close the day at $127.76. The stock recorded a trading volume of 6,198,989 shares, which was below its three months average volume of 6,499,828 shares. In the last year, Johnson & Johnson's shares have traded in a range of 118.62 - 148.32. The share price has gained 7.71% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $122.64 is below its 200-day moving average of $129.89. Shares of the company are trading at a Price to Earnings ratio of 282.65. Shares of Johnson & Johnson have gained roughly 4.26 percent in the past month and are down 8.56 percent year-to-date.
Access RDI's Johnson & Johnson Research Report at:
On Thursday, shares of AstraZeneca recorded a trading volume of 8,103,244 shares, which was above the three months average volume of 3,877,545 shares. The stock ended the day 4.29% higher at $36.96. The share price has fallen 0.91% from its 52 week high with a 52 week trading range of 28.43 - 37.30. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $36.19 is above its 200-day moving average of $35.18. Shares of the company are trading at a Price to Earnings ratio of 33.39. Shares of AstraZeneca have gained roughly 2.21 percent in the past month and are up 6.51 percent year-to-date.
Access RDI's AstraZeneca PLC Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Address: Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.